Biomind Labs Inc.
BMND
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.45M | -887.70K | -850.40K | -113.80K | -45.50K |
| Total Depreciation and Amortization | 0.00 | 0.00 | 2.20K | 4.40K | 6.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.09M | 531.20K | 458.90K | -281.20K | -353.40K |
| Change in Net Operating Assets | 129.00K | 222.70K | 321.80K | 269.40K | 198.70K |
| Cash from Operations | -232.70K | -134.00K | -67.50K | -121.20K | -193.60K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 209.30K | 157.40K | 86.40K | 150.10K | 140.90K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -5.10K |
| Cash from Financing | 209.30K | 157.40K | 86.40K | 150.10K | 135.80K |
| Foreign Exchange rate Adjustments | 23.30K | -9.00K | -18.90K | -2.20K | 25.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -200.00 | 14.30K | -100.00 | 26.60K | -33.00K |